Approximation error

Alcon Completes Availability of Clareon Portfolio with Clareon Toric During AAO 2022

Retrieved on: 
Thursday, September 29, 2022
Medical Supplies, Biotechnology, Technology, Health, Optical, Robotics, Health Technology, Medical Devices, Surgery, Audio, Video, Hardware, Adult, ROI, American Academy, Contraindication, Aphakia, ARGOS, Lists of diseases, Patient, Physician, Irritation, Bleeding, Central Time, Glaucoma, Eye, User, SMS, Cornea, Student, Visual acuity, Approximation error, Direction, Glasses, Surgeon, American Academy of Ophthalmology, Virtual reality, NYSE, Risk, ORA, News, Diabetes, Presbyopia, Region, Disorder, Light, AAO, SS, Eyelid, Incidence, Intraocular lens, Fidelis, Astigmatism, Retina, Maintenance, Patient satisfaction, Cataract, Life: A User's Manual, Quality of life, Use, Solution, Family, Red, Vision system, Iris, Swelling, Miyata, Telescopic sight, Medical imaging, Dentistry, Medicine, Alcon, IOL, Ophthalmology

Now, with the availability of Clareon Toric, I am able to offer my patients a glistening-free,* astigmatism-correcting option for them during surgery.

Key Points: 
  • Now, with the availability of Clareon Toric, I am able to offer my patients a glistening-free,* astigmatism-correcting option for them during surgery.
  • These activities will take place at Alcon booth #3926 at the AAO exhibit hall, on Oct. 1-3 from 9:00 a.m.5:00 p.m. Central Time.
  • The family of Clareon intraocular lenses (IOLs) includes the Clareon Aspheric Hydrophobic Acrylic and Clareon Aspheric Toric IOLs, the Clareon PanOptix Trifocal Hydrophobic IOL, Clareon PanOptix Toric, Clareon Vivity Extended Vision Hydrophobic Posterior Chamber IOL and Clareon Vivity Toric IOLs.
  • In addition, the Clareon Toric IOLs are indicated to correct pre-existing corneal astigmatism at the time of cataract surgery.

Scott Memorial Health Named LifePoint Health National Quality Leader

Retrieved on: 
Wednesday, September 28, 2022
Hospitals, Health, Nursing, Practice Management, Case management, Cardiology, Culture, Safety, Nuclear medicine, Nursing, Memorial, Endoscopy, Urology, Joint, Emergency department, Joint Commission, Scott, UMass Memorial Health, Patient, CEO, ICU, Solution, Obstetrics, National Association Medical Staff Services, CT, Patient safety, Pharmacy, Hospital, Approximation error, Norton Healthcare, Medicine, Management, Medical device, Gynaecology, Nephrology, LifePoint Health

Scott Memorial Health today announced that it has been named a LifePoint Health National Quality Leader.

Key Points: 
  • Scott Memorial Health today announced that it has been named a LifePoint Health National Quality Leader.
  • Achieving designation as a LifePoint Health National Quality Leader means our hospital sets the bar high in delivering high-quality care and providing exceptional service for those we are privileged to serve, said Martin Padgett, chief executive officer (CEO) of Scott Memorial Health.
  • To achieve LifePoint Health National Quality Leader designation, the Scott Memorial team worked to implement a number of best practices and launched new initiatives to engage patients and families, enhance patient safety and improve quality care.
  • Scott Memorial Health consistently delivers when it comes to ensuring the highest standards of quality and patient safety, and we are pleased to recognize this hospital as the newest LifePoint Health National Quality Leader, said Jason Zachariah, executive vice president and chief operating officer of LifePoint Health.

Brand Institute Partners on Brand Name Development for FDA-Approved Treatment for Prevention of Postoperative Nausea and Vomiting (PONV) in Adults

Retrieved on: 
Wednesday, September 28, 2022
Brand Institute, AMA, Safety, Food and Drug Administration, FDA, Food, Vomiting, World, Name, World Health Organization, Review, Approximation error, Therapy, Patient, Health Canada, Pharmacology, PONV, European Medicines Agency, WHO, American Medical Association, HC, Aprepitant, EMA, C.E.O, Pharmaceutical industry

APONVIE (aprepitant) is a substance P/neurokinin-1 receptor antagonist, indicated for the prevention of postoperative nausea and vomiting (PONV) in adults.

Key Points: 
  • APONVIE (aprepitant) is a substance P/neurokinin-1 receptor antagonist, indicated for the prevention of postoperative nausea and vomiting (PONV) in adults.
  • APONVIE is the first and only intravenous formulation of aprepitant for PONV prevention.
  • "The entire Brand Institute and Drug Safety Institute Team congratulates Heron Therapeutics on the FDA approval of APONVIE," said Brand Institute's Chairman and C.E.O., James L. Dettore.
  • The company partners on over 75% of pharmaceutical brand and nonproprietary name approvals globally every year with healthcare manufacturers.

PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

Retrieved on: 
Wednesday, September 28, 2022
Adult, Disability, Approximation error, Peptide, Therapy, Dystrophin, DM1, Safety, Incidence, HNV, Prevalence, Disease, Biomarker, Company, McArthur, Magnesium, Private Securities Litigation Reform Act, Achievement, Patient, Clinical trial, Primate, AES, CEO, EDO, Volunteering, Technology, Male, SAD, Nasdaq, SAE, CNS, Research, GLOBE, DMD, SEC, Myotonia, Marketing, PGN, Kidney, Webcast, Diaphragm, DMPK, Duchenne muscular dystrophy, Pharmaceutical industry, Medical imaging, Phosphorus, Fine chemical

PepGens Phase 1 HNV trial of PGN-EDO51 was a single ascending dose (SAD) clinical trial evaluating the safety and tolerability of PGN-EDO51 in 32 healthy adult males.

Key Points: 
  • PepGens Phase 1 HNV trial of PGN-EDO51 was a single ascending dose (SAD) clinical trial evaluating the safety and tolerability of PGN-EDO51 in 32 healthy adult males.
  • We are thrilled to announce that we have observed very high levels of oligonucleotide delivery and exon skipping in muscle in our Phase 1 HNV trial.
  • With the very encouraging outcome of this trial, PepGen plans to initiate a Phase 2a multiple ascending dose clinical trial in DMD patients in the first half of 2023.
  • Dr. McArthur added: We are particularly pleased with the high levels of exon skipping observed for PGN-EDO51 at 28 days.

Harrow Announces U.S. FDA Approval of IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia

Retrieved on: 
Wednesday, September 28, 2022
Institute, Safety, ASCRS, Efficiency, Risk, FDA, Food, Refractive surgery, American Society of Cataract and Refractive Surgery, Society, NDA, Intravitreal injection, PDUFA, Approximation error, Ophthalmology, Infection, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Orange Book, Cataract, Chloroprocaine, CA, Market, Research, Medicine, Optometry, Pharmaceutical industry, S.A

NASHVILLE, Tenn. and MENDRISIO, Switzerland, September 28, 2022 /PRNewswire/ -- Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, and Sintetica, S.A., a growing pharmaceutical company focused on analgesics, local anesthetics, and sterile injectable solutions, today jointly announced the U.S. Food and Drug Administration (FDA) approval of IHEEZO™ (chloroprocaine hydrochloride ophthalmic gel) 3% for ocular surface anesthesia. IHEEZO is a sterile, single-patient-use, physician-administered, ophthalmic gel preparation, containing no preservatives, that is safe and effective for ocular surface anesthesia. IHEEZO represents the first approved use in the U.S. ophthalmic market of chloroprocaine hydrochloride and the first branded ocular anesthetic approved for the U.S. ophthalmic market in nearly 14 years. IHEEZO is protected by an Orange Book-listed patent that is valid until 2038.

Key Points: 
  • IHEEZORepresentstheFirstApproved UseintheU.S.OphthalmicMarket of Chloroprocaine Hydrochloride and the First Branded Ocular Anesthetic Approved for the U.S. Ophthalmic Market in Nearly 14 Years
    IHEEZO was Licensed by Harrow for the U.S. and Canadian Markets From100-Year-OldInternationalPharmaceuticalCompanySintetica,S.A.
  • IHEEZO represents the first approved use in the U.S. ophthalmicmarketof chloroprocaine hydrochloride and the first branded ocular anesthetic approved for the U.S. ophthalmic market in nearly 14 years.
  • IHEEZO is protected by an Orange Book-listed patent that is valid until 2038.
  • Iwanttogivespecial thankstoourregulatorygroup, who while working with the Harrow team, performed extraordinarily well, resulting in this early U.S. market approval for this important new medicine."

Harrow Announces U.S. FDA Approval of IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia

Retrieved on: 
Wednesday, September 28, 2022
Institute, Safety, ASCRS, Efficiency, Risk, FDA, Food, Refractive surgery, American Society of Cataract and Refractive Surgery, Society, NDA, Intravitreal injection, PDUFA, Approximation error, Ophthalmology, Infection, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Optometry, Orange Book, Cataract, Chloroprocaine, CA, Market, Research, Medicine, Pharmaceutical industry, S.A

NASHVILLE, Tenn. and MENDRISIO, Switzerland, September 28, 2022 /PRNewswire/ -- Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, and Sintetica, S.A., a growing pharmaceutical company focused on analgesics, local anesthetics, and sterile injectable solutions, today jointly announced the U.S. Food and Drug Administration (FDA) approval of IHEEZO™ (chloroprocaine hydrochloride ophthalmic gel) 3% for ocular surface anesthesia. IHEEZO is a sterile, single-patient-use, physician-administered, ophthalmic gel preparation, containing no preservatives, that is safe and effective for ocular surface anesthesia. IHEEZO represents the first approved use in the U.S. ophthalmic market of chloroprocaine hydrochloride and the first branded ocular anesthetic approved for the U.S. ophthalmic market in nearly 14 years. IHEEZO is protected by an Orange Book-listed patent that is valid until 2038.

Key Points: 
  • NASHVILLE, Tenn. and MENDRISIO, Switzerland, September 28, 2022 /PRNewswire/ -- Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, and Sintetica, S.A., a growing pharmaceutical companyfocused onanalgesics,localanesthetics,andsterileinjectablesolutions,todayjointly announced the U.S. Food and Drug Administration (FDA) approval of IHEEZO (chloroprocaine hydrochloride ophthalmicgel)3%forocularsurface anesthesia.IHEEZOisasterile, single-patient-use, physician-administered,ophthalmicgelpreparation,containingnopreservatives,thatissafeandeffective for ocular surface anesthesia.
  • IHEEZO represents the first approved use in the U.S. ophthalmicmarketof chloroprocaine hydrochloride and the first branded ocular anesthetic approved for the U.S. ophthalmic market in nearly 14 years.
  • IHEEZO is protected by an Orange Book-listed patent that is valid until 2038.
  • Iwanttogivespecial thankstoourregulatorygroup, who while working with the Harrow team, performed extraordinarily well, resulting in this early U.S. market approval for this important new medicine."

Harrow Announces U.S. FDA Approval of IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia

Retrieved on: 
Tuesday, September 27, 2022
Research, Surgery, Medical Supplies, FDA, Clinical Trials, Biotechnology, Pharmaceutical, Health, Optical, Science, Institute, Safety, ASCRS, IV, Efficiency, COVID-19, Severe cognitive impairment, Risk, Refractive surgery, FDA, Food, Â, Anesthesia, American Society of Cataract and Refractive Surgery, Hypersensitivity, Society, Pharmacy, NDA, Intravitreal injection, PDUFA, Approximation error, Analgesic, Ophthalmology, Forward-looking statement, U.S. Securities and Exchange Commission, Infection, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, History, Eye, Physician, Orange Book, Full, Opacity (optics), Annual report, Cataract, Private Securities Litigation Reform Act, Patient safety, HCPS, Research, Security (finance), Marketing, SEC, Hospital, Optometry, Pharmaceutical industry, S.A

IHEEZO is a sterile, single-patientuse, physicianadministered, ophthalmic gel preparation, containing no preservatives, that is safe and effective for ocular surface anesthesia.

Key Points: 
  • IHEEZO is a sterile, single-patientuse, physicianadministered, ophthalmic gel preparation, containing no preservatives, that is safe and effective for ocular surface anesthesia.
  • IHEEZO represents the first approved use in the U.S. ophthalmic market of chloroprocaine hydrochloride and the first branded ocular anesthetic approved for the U.S. ophthalmic market in nearly 14 years.
  • Study 3 marks the first time a U.S. drug candidate was studied in a surgical model for FDA approval in the ocular surface anesthesia category.
  • Baum continued, Harrow currently provides perioperative medications for a significant number of the U.S. ophthalmic surgical procedures.

Patient-First Approach: How Technology is Filling the Gap in the Healthcare System

Retrieved on: 
Tuesday, September 27, 2022
Centers for Medicare & Medicaid Services, Center, Medicare, Risk, Long-term care, CMS, Health, Parikh, Approximation error, Patient, HCC, HIT, Physician, Technology, Population health, Hospice, Roger Hawkins (drummer), NLP, EMR, API, Natural language processing, Artificial intelligence, GLOBE, Software as a service, RAF, Medical device, Medicine, Health insurance, Pharmaceutical industry

Healthcare Information Technology (HIT) is offering healthcare providers and payers the next-generation solution to enhance patient safety by eliminating medication errors and improving healthcare quality.

Key Points: 
  • Healthcare Information Technology (HIT) is offering healthcare providers and payers the next-generation solution to enhance patient safety by eliminating medication errors and improving healthcare quality.
  • However, healthcare organizations must understand the importance of selecting the right technology to ensure patient safety.
  • Natural Language Processing (NLP) is making it easy for healthcare professionals to obtain patient-specific information, which can improve healthcare providers' decision-making to offer quality care.
  • RAAPIDs has been innovated to become the world's leading AI-based technology solution provider for a customizable risk adjustment landscape for value-based healthcare organizations.

Brand Institute Partners on Corporate Rebrand for Clinical Stage Biotechnology Company

Retrieved on: 
Monday, September 26, 2022
Brand Institute, AMA, Safety, Food and Drug Administration, FDA, Food, World, Name, World Health Organization, Review, Approximation error, Cancer, Health Canada, WHO, European Medicines Agency, American Medical Association, HC, EMA, Infection, C.E.O, Pharmaceutical industry

MIAMI, Sept. 26, 2022 /PRNewswire/ -- Brand Institute is proud to announce its work with Celsion Corporation in developing its new corporate name, Imunon, which was announced on September 19, 2022.

Key Points: 
  • MIAMI, Sept. 26, 2022 /PRNewswire/ -- Brand Institute is proud to announce its work with Celsion Corporation in developing its new corporate name, Imunon, which was announced on September 19, 2022.
  • Imunon, Inc. is reported to be a fully integrated, clinical stage biotechnology company establishing a leadership position in immunology.
  • "The entire Brand Institute and Drug Safety Institute Team congratulates Celsion on its name change to Imunon," said Brand Institute's Chairman and C.E.O., James L. Dettore.
  • The company partners on over 75% of pharmaceutical brand and nonproprietary name approvals globally every year with healthcare manufacturers.

Global Medical Simulation Market Report 2022: Industry to Grow at 13.3% Annually Through 2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, September 23, 2022
Health, Other Health, Nursing, SSH, Growth, News, Government, Cancer, NCBI, AIMS, Student, Medical simulation, Johns Hopkins University, Cardiovascular disease, Surgeon, Patient safety, Death, Motivation, Awareness, Approximation error, CAGR, Medical device, Pharmaceutical industry, Marketing

The "Global Medical Simulation Market Research and Forecast 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Medical Simulation Market Research and Forecast 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global medical simulation market is growing at a considerable CAGR of 13.3% during the forecast period (2021-2027).
  • Moreover, the need to increase patient safety and reduce medical errors is also estimated as one of the major factors.
  • Key companies operating in the global medical simulation market based on the availability of data, information related to new product launches, and relevant news is also available in the report.